Skip to main content
Clinical Trials/NCT02084355
NCT02084355
Unknown
Phase 3

Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study

Gyeongsang National University Hospital1 site in 1 country136 target enrollmentApril 2014

Overview

Phase
Phase 3
Intervention
oral oxycodone
Conditions
Cancer
Sponsor
Gyeongsang National University Hospital
Enrollment
136
Locations
1
Primary Endpoint
The rate of successful pain control defined as a 30% or 2-point reduction in the numeric rating scale
Last Updated
12 years ago

Overview

Brief Summary

Although opioid rotation is well known treatment modality in reducing pain and opioid-induced neurotoxicity, it is not established whether opioid rotation is more appropriate or opioid escalation is more effective in controlling significant pain in cancer patients under opioid medication.

  • The purpose of this study is to determine effective therapy out of opioid rotation and opioid dose escalation in patients with moderate to severe cancer pain who have been already treated with strong opioid.
Registry
clinicaltrials.gov
Start Date
April 2014
End Date
January 2016
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jung Hun Kang

Associate Professor

Gyeongsang National University Hospital

Eligibility Criteria

Inclusion Criteria

  • age \> 18 years
  • patients who are being treated with one of strong opioids including oral oxycodone, oral hydromorphone, or fentanyl patch with range from 60 mg to 200 mg of oral morphine equivalent daily dose (MEDD)
  • moderate to severe cancer pain (numeric rating scale more than 3) at screening
  • patients without uncontrolled adverse effects associated with currently applied opioid

Exclusion Criteria

  • previous opioid rotation
  • unable to take oral medication
  • life expectancy less than a month
  • newly started chemotherapy and/or radiotherapy within past 2 weeks of screening
  • serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase \> 2.5 times of upper normal limit
  • serum total bilirubin or creatinine \> 1.5 times of upper normal limit

Arms & Interventions

opioid rotation

Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids). * oral oxycodone : convert to oral hydromorphone or fentanyl patch * oral hydromorphone : convert to oral oxycodone or fentanyl patch * fentanyl patch : convert to oral oxycodone or oral hydromorphone

Intervention: oral oxycodone

opioid rotation

Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids). * oral oxycodone : convert to oral hydromorphone or fentanyl patch * oral hydromorphone : convert to oral oxycodone or fentanyl patch * fentanyl patch : convert to oral oxycodone or oral hydromorphone

Intervention: oral hydromorphone

opioid rotation

Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids). * oral oxycodone : convert to oral hydromorphone or fentanyl patch * oral hydromorphone : convert to oral oxycodone or fentanyl patch * fentanyl patch : convert to oral oxycodone or oral hydromorphone

Intervention: fentanyl patch

opioid dose escalation

Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid. * oral oxycodone : maintain oral oxycodone and titrate the dose * oral hydromorphone : maintain oral hydromorphone and titrate the dose * fentanyl patch : maintain fentanyl patch and titrate the dose

Intervention: oral oxycodone

opioid dose escalation

Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid. * oral oxycodone : maintain oral oxycodone and titrate the dose * oral hydromorphone : maintain oral hydromorphone and titrate the dose * fentanyl patch : maintain fentanyl patch and titrate the dose

Intervention: oral hydromorphone

opioid dose escalation

Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid. * oral oxycodone : maintain oral oxycodone and titrate the dose * oral hydromorphone : maintain oral hydromorphone and titrate the dose * fentanyl patch : maintain fentanyl patch and titrate the dose

Intervention: fentanyl patch

Outcomes

Primary Outcomes

The rate of successful pain control defined as a 30% or 2-point reduction in the numeric rating scale

Time Frame: Eighteen months

Study Sites (1)

Loading locations...

Similar Trials